- Home
- PINE vs GALT Comparison
PINE vs GALT Comparison
Compare PINE & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PINE | GALT |
|---|---|---|
| Founded | 2019 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.7M | 232.3M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PINE | GALT |
|---|---|---|
| Price | $17.52 | $5.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $17.67 | $6.00 |
| AVG Volume (30 Days) | 159.5K | ★ 431.4K |
| Earning Date | 10-23-2025 | 11-14-2025 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $57,423,000.00 | N/A |
| Revenue This Year | $14.13 | N/A |
| Revenue Next Year | $2.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.81 | N/A |
| 52 Week Low | $13.10 | $0.73 |
| 52 Week High | $17.88 | $6.66 |
Technical Indicators
Market Signals| Indicator | PINE | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 73.34 | 48.04 |
| Support Level | $17.10 | $5.67 |
| Resistance Level | $17.54 | $6.32 |
| Average True Range (ATR) | 0.41 | 0.51 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 78.62 | 25.00 |
Price Performance
Historical ComparisonAbout PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.